沃华医药(002107) - 2017 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2017 was ¥157,840,570.38, representing a 19.84% increase compared to ¥131,704,277.86 in the same period last year[9] - Net profit attributable to shareholders was ¥18,840,530.27, up 20.68% from ¥15,612,253.97 year-on-year[9] - The total profit for the period was ¥27,143,445.90, representing a growth of 32.33% year-on-year, driven by increased operating income and additional government subsidies received[17] - The net profit for the period was ¥24,041,075.01, reflecting a year-on-year increase of 35.30%, primarily due to the rise in total profit[18] - Basic earnings per share rose to ¥0.05, a 25.00% increase from ¥0.04 in the same quarter last year[9] Cash Flow - The net cash flow from operating activities increased by 107.00%, reaching ¥35,524,549.32 compared to ¥17,161,318.35 in the previous year[9] - The net cash flow from operating activities increased by ¥18,363,230.97 compared to the same period last year, attributed to a greater increase in operating cash income than in operating cash expenditures[18] - The net cash flow from financing activities increased by ¥10,295,804.57 compared to the previous year, mainly due to the payment made for the equity of Liaoning Kangchen Pharmaceutical Co., Ltd. in the prior year[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥739,788,129.84, reflecting a 4.84% increase from ¥705,626,466.89 at the end of the previous year[9] - The net assets attributable to shareholders increased by 3.85%, amounting to ¥507,856,236.27 compared to ¥489,016,058.70 at the end of the last year[9] - The balance of construction in progress at the end of the reporting period was ¥18,408,168.23, an increase of 70.41% compared to the beginning of the year, mainly due to increased investment in new extraction workshops during the reporting period[16] - The balance of taxes payable at the end of the reporting period was ¥11,574,787.12, up 33.74% from the beginning of the year, primarily due to an increase in corporate income tax payable[16] - The other current liabilities at the end of the reporting period were ¥22,897,183.48, an increase of 38.30% from the beginning of the year, mainly due to an increase in accrued sales expenses[16] Shareholder Information - The total number of common shareholders at the end of the reporting period was 41,955[12] - The largest shareholder, Beijing Zhongzheng Wanrong Investment Group Co., Ltd., held 50.27% of the shares, totaling 181,341,477 shares[12] - The company did not engage in any repurchase transactions during the reporting period[13] Non-Recurring Items - The company reported non-recurring gains and losses totaling ¥1,032,252.69 for the period[10] - The non-operating income for the period was ¥2,052,780.83, a substantial increase of 1315.45% year-on-year, primarily due to government support funds received by the subsidiary Jishun Pharmaceutical[16] Financial Expenses - The financial expenses for the period amounted to ¥2,274,754.88, a significant increase of 230.67% year-on-year, mainly due to a decrease in interest income compared to the previous year[16] Future Outlook - The operating income for the first half of 2017 is expected to show a net profit attributable to shareholders of the listed company ranging from ¥2,555.50 million to ¥3,833.26 million, reflecting a growth of 0.00% to 50.00% compared to the same period in 2016[21]